Article Resources: Long term treatment with low dose naltrexone (LDN) maintains stable health in patients with multiple sclerosis, chronic pain and fibromyalgia
Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone A Pilot Study:
This pilot study is the first to examine the effectiveness of LDN in reducing the symptoms of fibromyalgia. Overall symptom severity was significantly reduced in the drug condition, as contrasted to baseline and placebo conditions. In the entire group of participants, LDN reduced fibromyalgia symptoms by 30.2% over and above placebo. Specific symptoms, including average pain, highest pain, fatigue, and stress, were also significantly impacted by the drug. The observed effects were accompanied by a very low incidence of side effects, suggesting LDN may be an effective and well-tolerated treatment option for individuals with fibromyalgia.
Read more and download the pdf: Fibromyalgia Symptoms Are Reduced by Low Dose Naltrexone A Pilot Study
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis:
This study illustrates that LDN is safe for people with MS, particularly RRMS as it does not appear to increase MRI activity or alter regular blood tests of liver, kidney and hematopoietic function. The efficacy of LDN needs to be evaluated in prospective clinical studies of MS because of its interesting mechanism of action and preclinical data. The safety findings of our study indicate that prospective studies of up to 3 years could be safely performed. Evaluation of clinical values, behavior, and MRIs revealed that patients on a long-term LDN treatment regimen did not show that LDN alone increased inflammatory disease progression or impaired clinical blood values. These data could assist physicians in their decision to prescribe LDN as a safe, inexpensive therapy for MS patients who are reluctant to take other, more costly, or more cumbersome DMTs. Moreover, these data support and warrant prospective clinical studies of MS, examining treatment outcome in patients receiving LDN only.
Read more and download the pdf: Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis
Low-Dose Naltrexone for the Treatment of Fibromyalgia:
In this study, we found evidence that daily treatment with naltrexone (3.0–4.5 mg) reduces pain associated with fibromyalgia syndrome. The results largely support our earlier preliminary work (1), further suggesting a potential role of low-dose naltrexone in the treatment of fibromyalgia. The average reduction in pain we observed after 12 weeks of low-dose naltrexone administration was 28.8%, which was slightly lower than the average 32.5% reduction observed in our first trial. The percentages of participants who exhibited at least a 30% reduction in pain levels was very similar between the two studies, with a 57% pain response rate in the current study and a 60% response rate in the previous study. Unlike the first study, however, we did not find an effect of low-dose naltrexone on fatigue. The collective results suggest that low-dose naltrexone.
Read more and download the pdf: Low-Dose Naltrexone for the Treatment of Fibromyalgia
Reduced Pro-Inﬂammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia:
The goal of this study was to test if LDN administration is associated with reduced markers of inflammation in FM. We found that, after eight weeks of LDN administration, plasma levels of a range of broadly pro-inflammatory cytokines were decreased. In addition, we found that participants reported less pain and symptoms following LDN. Combined, these results support the hypothesis that LDN may help chronic pain conditions, such as fibromyalgia, by acting as an atypical antiinflammatory medication.
Read more and download the pdf: Reduced Pro Inﬂammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain:
The totality of the basic and clinical research to date suggests that LDN is a promising treatment approach for chronic pain conditions thought to involve inflammatory processes. The clinical data supporting its use are very preliminary, and more research is needed before the treatment approach can be widely recommended. Critical parameters such as dosing still need to be refined. LDN may emerge as the first of many glial cell modulators that could be used to treat chronic conditions, with more specifically targeted medications developed in the future. As conventional anti-inflammatories have poor blood brain-barrier permeability, we expect centrally active immune modulators to be an area of interest in the future.
Read more and download the pdf: The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
Treatment of Complex Regional Pain Syndrome CRPS Using Low-Dose Naltrexone (LDN):
Our use of LDN treatment for CRPS patients was motivated by a presumed neuroinflammatory etiology for longstanding CRPS symptoms. The remission of pain and dystonic spasms in Case 1, as well a remission of all CRPS symptoms (including fixed dystonia) in Case 2, provide evidence that a multi-modal interventional approach, which includes low-dose naltrexone (a known glial attenuator), should be considered as a treatment option for the treatment of CRPS patients, particularly those patients with dystonic movement disorders.
Read more and download the pdf: Treatment of Complex Regional Pain Syndrome CRPS Using Low-Dose Naltrexone (LDN)
Contact Us For More Information on Compound Prescriptions
American Integrative Pharmacy is located in Torrance, CA serving residents in and around Orange County, Los Angeles, Long Beach, Lomita and surrounding areas. Online prescription sales are available across the US.